Menu Search
Equities

Human Metabolome Technologies Inc

6090:TYO

Human Metabolome Technologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)619.00
  • Today's Change-1.00 / -0.16%
  • Shares traded5.20k
  • 1 Year change-15.78%
  • Beta1.3183
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Human Metabolome Technologies Inc's net income fell -14.88% from 285.76m to 243.25m despite revenues that grew 3.57% from 1.30bn to 1.35bn. An increase in the selling, general and administrative costs as a percentage of sales from 34.94% to 48.24% was a component in the falling net income despite rising revenues.
Gross margin64.60%
Net profit margin18.08%
Operating margin17.88%
Return on assets9.94%
Return on equity13.08%
Return on investment12.91%
More ▼

Cash flow in JPYView more

In 2024, Human Metabolome Technologies Inc increased its cash reserves by 7.95%, or 131.72m. The company earned 236.80m from its operations for a Cash Flow Margin of 17.60%. In addition the company used 32.44m on investing activities and also paid 73.15m in financing cash flows.
Cash flow per share49.42
Price/Cash flow per share12.55
Book value per share329.08
Tangible book value per share326.13
More ▼

Balance sheet in JPYView more

Human Metabolome Technologies Inc appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 1.79bn. In fact, 0.49% of the value of Human Metabolome Technologies Inc shares can be attributed to this cash.
Current ratio3.31
Quick ratio3.25
Total debt/total equity0.1163
Total debt/total capital0.1041
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.